Deletion in a regulatory region is associated with underexpression of miR-148b‑3p in patients with prostate cancer

Bergez‑Hernández,Fernando; Luque‑Ortega,Fred; García‑Magallanes,Noemí; Alvarez‑Arrazola,Marco; Arámbula‑Meraz,Eliakym

doi:10.3892/br.2024.1740

Deletion in a regulatory region is associated with underexpression of miR-148b‑3p in patients with prostate cancer

Authors:
- Fernando Bergez‑Hernández
- Fred Luque‑Ortega
- Noemí García‑Magallanes
- Marco Alvarez‑Arrazola
- Eliakym Arámbula‑Meraz
View Affiliations

Affiliations: Postgraduate in Biomedical Sciences, Faculty of Chemical‑Biological Sciences, Autonomous University of Sinaloa, Culiacán, 80010 Sinaloa, México, Basic Sciences Laboratory, Faculty of Dentistry, Autonomous University of Sinaloa, Culiacán, 80100 Sinaloa, México, Laboratory of Biomedicine and Molecular Biology, Biotechnology Engineering, Polytechnic University of Sinaloa, Mazatlán, 82199 Sinaloa, México, Alvarez and Arrazola Radiologists, Mazatlán, 82140 Sinaloa, México
Published online on: January 30, 2024 https://doi.org/10.3892/br.2024.1740
Article Number: 52
Copyright: © Bergez‑Hernández et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer (PCa) is the leading cause of cancer‑related death in men. This pathology is complex and heterogeneous; therefore, elucidating the molecular mechanisms that lead to its origin and progression is imperative. MicroRNAs (miRNAs or miRs) are part of the epigenetic machinery that regulates the expression of human genes, therefore, mutations in the genes that encode them can lead to a dysregulation in their expression, which directly impacts their target genes, which could be oncogenes or tumor suppressor genes. In PCa several dysregulated expression levels of miRNAs are associated with perturbed cellular processes. A differential expression of miRNAs such as miR-145‑5p and miR-148‑3p has been observed in PCa, possibly due to mutations in regions near the miRNAs. However, the molecular mechanisms that lead to the dysregulation of these miRNAs still need to be clarified. Therefore, the present study aimed to analyze the expression of miRNAs and their relationship with mutations in patients with and without PCa. In total, 71 patients were analyzed: 41 of whom had PCa (CAP group) and 30 with benign pathology (BPD group). Underexpression was observed in miR-145‑5p and miR-148b‑3p in PCa patients (P=0.03 and P=0.001, respectively). In miR-145‑5p, no mutations related to its expression were identified. For miR-148b‑3p, a set of mutations were identified in the chr12:54337042/54337043 region, which were grouped into the mutation named DelsAAG. Although this mutation's abnormal allele is related to PCa (P=0.017), a statistically significant difference was observed in the expression of miR-148b‑3p between carriers and non‑carriers of the mutated allele, identifying a mechanism likely to be involved in the miR-148b‑3p dysregulation.

View Figures

View References

1	Xiao J, Gong AY, Eischeid AN, Chen D, Deng C, Young CY and Chen XM: miR-141 modulates androgen receptor transcriptional activity in human prostate cancer cells through targeting the small heterodimer partner protein. Prostate. 72:1514–1522. 2012.PubMed/NCBI View Article : Google Scholar
2	Sun Q, Zhao X, Liu X, Wang Y, Huang J, Jiang B, Chen Q and Yu J: miR-146a functions as a tumor suppressor in prostate cancer by targeting Rac1. Prostate. 74:1613–1621. 2014.PubMed/NCBI View Article : Google Scholar
3	Bergez-Hernández F, Arámbula-Meraz E, Alvarez-Arrazola M, Irigoyen-Arredondo M, Luque-Ortega F, Martínez-Camberos A, Cedano-Prieto D, Contreras-Gutiérrez J, Martínez-Valenzuela C and García-Magallanes N: Expression Analysis of miRNAs and their potential role as biomarkers for prostate cancer detection. Am J Mens Health. 16(15579883221120989)2022.PubMed/NCBI View Article : Google Scholar
4	Arámbula-Meraz E, Bergez-Hernández F, Leal-León E, Romo-Martínez E, Picos-Cárdenas V, Luque-Ortega F, Romero-Quintana J, Alvarez-Arrazola M and García-Magallanes N: Expression of miR-148b-3p is correlated with overexpression of biomarkers in prostate cancer. Genet Mol Biol. 43(e20180330)2020.PubMed/NCBI View Article : Google Scholar
5	Xu WX, Liu Z, Deng F, Wang DD, Li XW, Tian T, Zhang J and Tang JH: MiR-145: A potential biomarker of cancer migration and invasion. Am J Transl Res. 11:6739–6753. 2019.PubMed/NCBI
6	Jin W, Fei X, Wang X, Song Y and Chen F: Detection and prognosis of prostate cancer using blood-based biomarkers. Mediators Inflamm. 2020(8730608)2020.PubMed/NCBI View Article : Google Scholar
7	Chu H, Zhong D, Tang J, Li J, Xue Y, Tong N, Qin C, Yin C, Zhang Z and Wang M: A functional variant in miR-143 promoter contributes to prostate cancer risk. Arch Toxicol. 90:403–414. 2016.PubMed/NCBI View Article : Google Scholar
8	Kotarac N, Dobrijevic Z, Matijasevic S, Savic-Pavicevic D and Brajuskovic G: Analysis of association of potentially functional genetic variants within genes encoding miR-34b/c, miR-378 and miR-143/145 with prostate cancer in Serbian population. EXCLI J. 18:515–529. 2019.PubMed/NCBI View Article : Google Scholar
9	Watahiki A and Wang Y, Morris J, Dennis K, O'Dwyer HM, Gleave M, Gleave M, Gout PW and Wang Y: MicroRNAs associated with metastatic prostate cancer. PLoS One. 6(e24950)2011.PubMed/NCBI View Article : Google Scholar
10	Chen X, Wang G, Lu X, Gao P, Song Y, Sun J, Li A, Xu Y, Xu H and Wang Z: Polymorphisms and haplotypes of the miR-148/152 family are associated with the risk and clinicopathological features of gastric cancer in a Northern Chinese population. Mutagenesis. 29:401–407. 2014.PubMed/NCBI View Article : Google Scholar
11	Chomczynski P: A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques. 15:532–4, 536-7. 1993.PubMed/NCBI
12	Kim YG, Kim MJ, Lee JS, Lee JA, Song JY, Cho SI, Park SS and Seong MW: SnackVar: An open-source software for sanger sequencing analysis optimized for clinical use. J Mol Diagn. 23:140–148. 2021.PubMed/NCBI View Article : Google Scholar
13	Rijk PD and Del-Favero J: novoSNP3: Variant detection and sequence annotation in resequencing projects. Methods Mol Biol. 396:331–344. 2007.PubMed/NCBI View Article : Google Scholar
14	Taylor SC, Nadeau K, Abbasi M, Lachance C, Nguyen M and Fenrich J: The Ultimate qPCR experiment: Producing publication quality, reproducible data the first time. Trends Biotechnol. 37:761–774. 2019.PubMed/NCBI View Article : Google Scholar
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
16	Akalin I, Erol B, Aslan E, Ozkanli SS, Efiloglu O, Yildirim S, Caskurlu T, Yildirim A and Karaman MI: A new promising pathway in aggressive prostate cancer: Treg/mir-let8c/lin28b. Arch Esp Urol. 75:459–466. 2022.PubMed/NCBI View Article : Google Scholar
17	Liu S, Zhao Y, Zhao Y and Tang X: The prognostic value of miR-487a in clear cell renal cell carcinoma and its influence on cell biological behavior. Arch Esp Urol. 75:346–353. 2022.PubMed/NCBI View Article : Google Scholar
18	Wang Z, Zhu X, Zhai H, Wang Y and Hao G: Integrated analysis of mRNA-single nucleotide polymorphism-microRNA interaction network to identify biomarkers associated with prostate cancer. Front Genet. 13(922712)2022.PubMed/NCBI View Article : Google Scholar
19	Camargo JA, Lopes RE, Ferreira GFD, Viana NI, Guimaraes V, Leite KRM, Nahas WC, Srougi M, Antunes AA and Reis ST: The role of single nucleotide polymorphisms of miRNAs 100 and 146a as prognostic factors for prostate cancer. Int J Biol Markers. 36:50–56. 2021.PubMed/NCBI View Article : Google Scholar
20	Xu B, Feng NH, Li PC, Tao J, Wu D, Zhang ZD, Tong N, Wang JF, Song NH, Zhang W, et al: A functional polymorphism in Pre-miR-146a gene is associated with prostate cancer risk and mature miR-146a expression in vivo. Prostate. 70:467–472. 2010.PubMed/NCBI View Article : Google Scholar
21	Huang S, Cui H, Lou Z, Wang X, Chen L, Xie Z, Hehir M, Yao X, Ren Y, Cen D and Weng G: Association of rs3787016 in Long Non-coding RNAs POLR2E and rs2910164 in MiRNA-146a with prostate cancer: A systematic review and meta-analysis. Iran J Public Health. 47:623–632. 2018.PubMed/NCBI
22	Zhao CG, Xu HB and Xu B: The rs4705342 gene mutation in the promoter region of the miR-143/145 cluster associated with the risk of prostate cancer in the Chinese Han population. Zhonghua Nan Ke Xue. 25:696–702. 2019.PubMed/NCBI(In Chinese).
23	Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM and Sirotkin K: dbSNP: The NCBI database of genetic variation. Nucleic Acids Res. 29:308–311. 2001.PubMed/NCBI View Article : Google Scholar
24	Chacon-Cortes D, Smith RA, Haupt LM, Lea RA, Youl PH and Griffiths LR: Genetic association analysis of miRNA SNPs implicates MIR145 in breast cancer susceptibility. BMC Med Genet. 16(107)2015.PubMed/NCBI View Article : Google Scholar
25	Zaman MS, Chen Y, Deng G, Shahryari V, Suh SO, Saini S, Majid S, Liu J, Khatri G, Tanaka Y and Dahiya R: The functional significance of microRNA-145 in prostate cancer. Br J Cancer. 103:256–264. 2010.PubMed/NCBI View Article : Google Scholar
26	Bellissimo T, Ganci F, Gallo E, Sacconi A, Tito C, De Angelis L, Pulito C, Masciarelli S, Diso D, Anile M, et al: Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation. Mol Cancer. 16(88)2017.PubMed/NCBI View Article : Google Scholar
27	Donzelli S, Mori F, Bellissimo T, Sacconi A, Casini B, Frixa T, Roscilli G, Aurisicchio L, Facciolo F, Pompili A, et al: Epigenetic silencing of miR-145-5p contributes to brain metastasis. Oncotarget. 6:35183–35201. 2015.PubMed/NCBI View Article : Google Scholar
28	Xue G, Ren Z, Chen Y, Zhu J, Du Y, Pan D, Li X and Hu B: A feedback regulation between miR-145 and DNA methyltransferase 3b in prostate cancer cell and their responses to irradiation. Cancer Lett. 361:121–127. 2015.PubMed/NCBI View Article : Google Scholar
29	Suh SO, Chen Y, Zaman MS, Hirata H, Yamamura S, Shahryari V, Liu J, Tabatabai ZL, Kakar S, Deng G, et al: MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis. 32:772–778. 2011.PubMed/NCBI View Article : Google Scholar
30	Nesta AV, Tafur D and Beck CR: Hotspots of human mutation. Trends Genet. 37:717–729. 2021.PubMed/NCBI View Article : Google Scholar
31	Gemayel R, Cho J, Boeynaems S and Verstrepen KJ: Beyond junk-variable tandem repeats as facilitators of rapid evolution of regulatory and coding sequences. Genes (Basel). 3:461–480. 2012.PubMed/NCBI View Article : Google Scholar
32	Vieira ML, Santini L, Diniz AL and Munhoz Cde F: Microsatellite markers: What they mean and why they are so useful. Genet Mol Biol. 39:312–328. 2016.PubMed/NCBI View Article : Google Scholar
33	Fishilevich S, Nudel R, Rappaport N, Hadar R, Plaschkes I, Iny Stein T, Rosen N, Kohn A, Twik M, Safran M, et al: GeneHancer: Genome-wide integration of enhancers and target genes in GeneCards. Database (Oxford). 2017(bax028)2017.PubMed/NCBI View Article : Google Scholar
34	Peng Y and Zhang Y: Enhancer and super-enhancer: Positive regulators in gene transcription. Animal Model Exp Med. 1:169–179. 2018.PubMed/NCBI View Article : Google Scholar
35	Cunningham F, Allen JE, Allen J, Alvarez-Jarreta J, Amode MR, Armean IM, Austine-Orimoloye O, Azov AG, Barnes I, Bennett R, et al: Ensembl 2022. Nucleic Acids Res. 50:D988–D995. 2022.PubMed/NCBI View Article : Google Scholar
36	Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, Major F, Ferbeyre G and Chartrand P: An E2F/miR-20a autoregulatory feedback loop. J Biol Chem. 282:2135–2143. 2007.PubMed/NCBI View Article : Google Scholar
37	Woods K, Thomson JM and Hammond SM: Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem. 282:2130–2134. 2007.PubMed/NCBI View Article : Google Scholar
38	de Santiago I, Liu W, Yuan K, O'Reilly M, Chilamakuri CS, Ponder BA, Meyer KB and Markowetz F: BaalChIP: Bayesian analysis of allele-specific transcription factor binding in cancer genomes. Genome Biol. 18(39)2017.PubMed/NCBI View Article : Google Scholar
39	Huang Q, Whitington T, Gao P, Lindberg JF, Yang Y, Sun J, Väisänen MR, Szulkin R, Annala M, Yan J, et al: A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding. Nat Genet. 46:126–135. 2014.PubMed/NCBI View Article : Google Scholar
40	Zhang P, Tillmans LS, Thibodeau SN and Wang L: Single-Nucleotide polymorphisms sequencing identifies candidate functional variants at prostate cancer risk loci. Genes (Basel). 10(547)2019.PubMed/NCBI View Article : Google Scholar
41	Eickhardt E, Als TD, Grove J, Boerglum AD and Lescai F: Estimating the functional impact of INDELs in transcription factor binding sites: A Genome-Wide Landscape. Bioinformatics, 2016 Jun. Available from: http://biorxiv.org/lookup/doi/10.1101/057604.
42	Tomeva E, Switzeny OJ, Heitzinger C, Hippe B and Haslberger AG: Comprehensive approach to distinguish patients with solid tumors from healthy controls by combining androgen receptor mutation p. H875Y with Cell-Free DNA methylation and circulating miRNAs. Cancers (Basel). 14(462)2022.PubMed/NCBI View Article : Google Scholar
43	Feng F, Liu H, Chen A, Xia Q, Zhao Y, Jin X and Huang J: miR-148-3p and miR-152-3p synergistically regulate prostate cancer progression via repressing KLF4. J Cell Biochem. 120:17228–17239. 2019.PubMed/NCBI View Article : Google Scholar
44	Wei LZ, Wang YQ, Chang YL, An N, Wang X, Zhou PJ, Zhu HH, Fang YX and Gao WQ: Imbalance of a KLF4-miR-7 auto-regulatory feedback loop promotes prostate cancer cell growth by impairing microRNA processing. Am J Cancer Res. 8:226–244. 2018.PubMed/NCBI
45	Siu MK, Suau F, Chen WY, Tsai YC, Tsai HY, Yeh HL and Liu YN: KLF4 functions as an activator of the androgen receptor through reciprocal feedback. Oncogenesis. 5(e282)2016.PubMed/NCBI View Article : Google Scholar
46	Desai K, McManus JM and Sharifi N: Hormonal therapy for prostate cancer. Endocr Rev. 42:354–373. 2021.PubMed/NCBI View Article : Google Scholar
47	Auchus RJ and Sharifi N: Sex Hormones and Prostate Cancer. Annu Rev Med. 71:33–45. 2020.PubMed/NCBI View Article : Google Scholar